This site is intended for healthcare professionals only
Share this article

NICE approves three SGLT2 inhibitors as monotherapy

NICE have released a new technology appraisal recommending three sodium–glucose cotransporter 2 (SGLT2) inhibitors – canagliflozin (Invokana; Janssen), dapagliflozin (Forxiga; AstraZeneca) and empagliflozin (Jardiance; Boehringer Ingelheim and Lilly UK) – as monotherapies for people with type 2 diabetes.

The treatments are recommended as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control. However, they are only recommended if a dipeptidyl peptidase‑4 (DPP‑4) inhibitor would otherwise be prescribed, and if a sulfonylurea or pioglitazone is not appropriate.

Adults who are not recommended to receive monotherapy with these agents in the new guidance but who had already started before publication should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

The guidance and evidence base can be read in full at

Related content
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.